dyslipidemia - Cleveland Clinic

Tag debug info: client: {"assets":{},"datasets":{},"live":{},"projects":{},"users":{},"observable":{"assets":{},"datasets":{},"live":{},"projects":{},"users":{}}}
Now: 1770466442484
Cache Key: cqdTagPageBySlug:dyslipidemia
fetchCache[cqdTagPageBySlug:dyslipidemia].expirationTime: falsey
fetchCache[cqdTagPageBySlug:dyslipidemia]. seconds remaining: falsey
All fetchCache expiration times:
-- Key: cqdNotFoundPage, seconds remaining: -8
-- Key: cqdTagPageBySlug:ocular-adnexal-lymphoma, seconds remaining: -64980
-- Key: cqdPostsByTag:cqd-migrated-tag-3216,1,10, seconds remaining: -64921
-- Key: cqdTagPageBySlug:high-sensitivity-cardiac-troponins-hsctnt, seconds remaining: -8
-- Key: cqdPostsByTag:cqd-migrated-tag-23276,1,10, seconds remaining: 62
conditions:
-- false,
-- NA,
-- NA,
-- NA
-- false
Cache miss for key cqdTagPageBySlug:dyslipidemia - retrieving from Sanity
CCCache.dataFetchCount: 2670
Cache cleanup seconds remaining: 19992

Tag: dyslipidemia

CRISPR-Cas9 Gene Editing for Refractory Dyslipidemia Shows Safety and Preliminary Efficacy

Large Cohort Study Reveals Vanishingly Small Rates of Lipoprotein(a) Testing

Lepodisiran’s Large, Durable Lp(a) Reductions in Phase 2 Trial Boost Anticipation of Phase 3 Results

Web App Enables Safe, Effective Nonprescription Statin Use

Link Discovered Between Excess Niacin and Cardiovascular Disease

Lipoprotein(a): Progress on One of the Last Untreatable Frontiers of Cardiovascular Risk

Novel siRNA Reduces Lipoprotein(a) by More Than 90% for 48 Weeks

Dietary Supplements Don’t Stack Up to Low-Dose Statin Therapy for LDL-C Reduction

Novel siRNA Therapy Lowers Elevated Plasma Lipoprotein(a) in Phase 1 APOLLO Trial

Research Reveals Potential Drug Target for Treating Obesity and Other Metabolic Conditions